BACKGROUND: BAFF (B-cell activating factor of the tumor necrosis factor family) and APRIL (a proliferation-inducing ligand) are two of the major survival factors for B cells. Many studies have shown that BAFF levels were elevated in MSers. However, whether the levels of CSF BAFF/APRIL increased in NMOers was still unclear.
METHODS: CSF BAFF and APRIL was measured by an enzyme-linked immunosorbent assay (ELISA) in NMOers (n = 22), MSers (n = 18) and controls (n = 14).
RESULTS: Concentration of BAFF and APRIL in NMOers were significantly higher than in MSers and controls. CSF BAFF and APRIL levels in controls were also lower than MS. Both NMO and MS revealed an increased disease disability with increased CSF BAFF. CSF APRIL was associated with EDSS scores in NMO, but not found in MSers.
CONCLUSIONS: BAFF/APRIL system considered important for aggressive B cells and T-cell responses, and may stimulates B cells and T cell activation in acute relapse of NMO and MS. In NMOers, CSF BAFF and APRIL may be key factors of B cell immune response and reflect disease severity.
ECTRIMS 2011: B cell targeting can trigger relapses
08 Nov 2011
L. Kappos, H-P. Hartung, M. S. Freedman, A. Boyko, D. Mikol, U. Freudensprung, T. Plitz for the ATAMS study group ATAMS: a randomised trial of the B-cell-targeting agent atacicept in patients with relapsing multiple sclerosis.
Multiple Sclerosis Research: Research: B cells Abit late Now
29 Mar 2012
It has already been shown that rituximab and ocreluzimab (B cell blocking agents) can inhibit some aspects of MS whilst Atacicept another B cell blocking agent makes MS worse. My old Boss (John Leslie Turk) reported on B …